Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

849
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
849
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

818
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
818
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

962
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
962
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contrast-enhanced ultrasonography vs MRI for indeterminate testicular lesions: a systematic review and meta-analysis.

BJU international·2026
Same author

Long-term sexual function, fertility, and quality of life after childhood treatment for posterior urethral valves: a systematic review of clinical outcomes.

The journal of sexual medicine·2026
Same author

Awareness, use, and perceived barriers to artificial intelligence in pediatric urology: a multicenter survey.

Therapeutic advances in urology·2026
Same author

Efficacy and safety of low-power holmium laser enucleation of the prostate: experience gained from more than 700 cases.

Turkish journal of medical sciences·2025
Same author

Summary of the European Association of Urology/European Society of paediatric urology guidelines on transition in urology.

Journal of pediatric urology·2025
Same author

Neuroimaging Findings and Neurocognitive Features of Patients with Ochoa Syndrome (Urofacial Syndrome)-A Prospective Experimental Study.

Diagnostics (Basel, Switzerland)·2025
Same journal

Sacral Neuromodulation in the Management of Refractory Pediatric Lower Urinary Tract Dysfunction.

Neurourology and urodynamics·2026
Same journal

Response to the Letter to the Editor on "Effect of Acupressure on Anxiety, Embarrassment, and Procedural Fear in Patients Undergoing Urodynamic Testing: Randomized Controlled Study".

Neurourology and urodynamics·2026
Same journal

Response to the Letter to the Editor on "Effect of Acupressure on Anxiety, Embarrassment, and Procedural Fear in Patients Undergoing Urodynamic Testing: Randomized Controlled Study".

Neurourology and urodynamics·2026
Same journal

The Importance of Video Urodynamics in Selected Oligo-Anuric Patients Awaiting Renal Transplantation.

Neurourology and urodynamics·2026
Same journal

Prior Authorization for Sacral Nerve Stimulation in the Era of WISeR: Evaluation of U.S. Payer Coverage Policies.

Neurourology and urodynamics·2026
Same journal

Advancing Personalized Care for Neurogenic Bladder: The Case for Continent Urinary Diversion.

Neurourology and urodynamics·2026
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

12.2K

Predictive Factors for Complete Treatment Response in Structured Giggle Incontinence Treatment.

Araz Musaev1, Berat Daşkıran1, Can Sicimli1

  • 1Department of Urology, Ankara University School of Medicine, Division of Pediatric Urology, Ankara, Turkey.

Neurourology and Urodynamics
|March 18, 2026
PubMed
Summary
This summary is machine-generated.

Biofeedback therapy offers superior long-term results for giggle incontinence (GI) compared to anticholinergics, especially in refractory cases. Factors like post-pubertal age and female sex predict treatment success in GI management.

Keywords:
biofeedbackenuresis risoriigiggle incontinencelaughtermethylphenidate

Related Experiment Videos

Last Updated: Mar 19, 2026

Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

12.2K

Area of Science:

  • Pediatric Urology
  • Functional Urology
  • Behavioral Medicine

Background:

  • Giggle incontinence (GI) is a condition characterized by involuntary urine leakage during laughter.
  • Management of GI often involves a stepwise approach, but factors influencing treatment response require further elucidation.

Purpose of the Study:

  • To compare the efficacy of anticholinergics versus biofeedback (BF) in patients with GI.
  • To identify clinical and demographic predictors of complete treatment response (CTR) to a structured GI management protocol.

Main Methods:

  • A retrospective evaluation of 133 patients treated for GI between 2010 and 2025.
  • Patients not achieving CTR and requiring methylphenidate were randomized to receive either standard urotherapy plus anticholinergics (Group 1) or standard urotherapy plus biofeedback (Group 2).

Main Results:

  • Post-pubertal age, female sex, and positive family history were associated with CTR in both groups.
  • While initial CTR rates were similar, Group 2 (biofeedback) demonstrated significantly higher CTR at 6 and 12 months compared to Group 1 (anticholinergics) (p < 0.05).
  • No significant association was found with BMI, DVISS, constipation, or enuresis.

Conclusions:

  • Post-pubertal age, female gender, and family history are predictors of CTR for both anticholinergic and biofeedback treatments in GI.
  • In refractory GI cases, a history of biofeedback therapy is linked to sustained long-term CTR when methylphenidate is added.